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ORIGINAL INVESTIGATION
Left ventricular concentric geometry 
predicts incident diabetes mellitus independent 
of established risk factors in the general 
population: the Copenhagen City Heart Study
Daniel Modin1* , Rasmus Møgelvang1,2, Peter Godsk Jørgensen1, Magnus Thorsten Jensen1, 
Jelena P. Seferovic3 and Tor Biering‑Sørensen1,4
Abstract 
Background: Subtle impairments in left ventricular (LV) function and geometry are common findings in individu‑
als with diabetes. However, whether these impairments precede the development of diabetes mellitus (DM) is not 
entirely clear.
Methods: Echocardiograms from 1710 individuals from the general population free of prevalent diabetes mellitus 
were analyzed. Left ventricular (LV) concentric geometry was defined as either LV concentric remodeling or LV con‑
centric hypertrophy as directed in contemporary guidelines. The severity of LV concentricity was assessed by relative 
wall thickness (RWT) calculated as posterior wall thickness (PWT) indexed to left ventricular internal diameter at end 
diastole (LVIDd) (RWT = 2 * PWT/LVIDd). End‑point was incident DM.
Results: Median follow‑up time was 12.6 years (IQR: 12.0–12.8 years). Follow‑up was a 100%. A total of 55 participants 
(3.3%) developed DM during follow‑up. At baseline, the prevalence of a concentric LV geometric pattern was signifi‑
cantly higher (41.8% vs 20.3%, p < 0.001) in individuals who developed DM during follow‑up. In a final multivariable 
model adjusting for established DM risk factors including HbA1c, BMI and plasma glucose, LV concentric geometry 
and RWT remained significantly associated with incident DM (LV concentric geometry: HR 1.99, 95% CI 1.11–3.57, 
p = 0.021) (RWT: HR 1.41, 95% CI 1.06–1.86, p = 0.017, per 0.1 increase). This association remained despite adjustment 
for established risk factors for DM.
Conclusion: Altered LV geometry may precede the development of DM. LV concentric geometry determined by 
echocardiography and the severity of LV concentricity evaluated as RWT are associated with incident DM in the gen‑
eral population.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Diabetes mellitus (DM) is a major risk factor for cardio-
vascular disease (CVD) [1], and the increasing preva-
lence of DM in the years to come represents one of the 
greatest threats to public health. In 2012, in the US, 1 
out of every 11 individuals was living with diabetes, and 
1 out of every 3rd adult was living with prediabetes [2]. 
In 2012, this astronomical burden of disease resulted in 
a cost of 245 billion dollars in the US alone [2]. Since 
many risk factors for diabetes are modifiable, identifi-
cation of individuals at high risk of developing diabe-
tes is needed to initiate preventive measures as early as 
possible.
Glucose homeostasis is closely tied to cardiovascu-
lar pathology, and even in subjects not diagnosed with 
fulminant DM, dysfunctional glucose homeostasis sig-
nificantly increases the risk of CVD [3]. Cross-sectional 
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studies have demonstrated impairments in diastolic func-
tion and increases in left ventricular (LV) mass and wall 
thickness to be the first manifestations of myocardial 
involvement in DM [4, 5]. These changes are character-
istic of the cardiac impairment observed in diabetes [6]. 
Specifically, a concentric LV geometric pattern quantified 
by relative wall thickness has been tied to DM and abnor-
mal glucose homeostasis [7].
Recently, evidence has indicated that myocardial 
involvement and early diastolic dysfunction may pre-
cede the development of DM [8–10]. This suggests 
that indices of myocardial structure and function may 
offer information value in predicting DM. Only one 
study, published in March 2017, have investigated the 
prognostic value of myocardial indices derived from 
echocardiography with regards to the development of 
DM in the general population [9]. However, this study 
employed multivariable logistic regression and not 
survival analysis to assess the predictive value of echo-
cardiography, and the general population was set in 
Korea [9], making the results not directly applicable to 
Caucasians taking into account that ethnicity in itself 
is a significant risk factor for DM, and that ethnicity 
modifies the relationship between several risk factors 
and DM [11, 12]. Thus, this study sought to determine 
the prognostic role of echocardiography in predicting 
incident DM in a general population of European ori-
gin. Finally, in addition to improving risk stratification, 
the results of this study may also help to shed more 
light on the conundrum that is diabetic cardiomyopa-
thy today [13].
Methods
Data availability
The data, analytic methods, and study materials will 
not be made available to other researchers for purposes 
of reproducing the results or replicating the procedure. 
The data analysed in this paper is governed by the Dan-
ish Data Protection Agency and can only be made avail-
able for any additional researcher if a formal application 
is made to the Danish authorities.
Population
The Copenhagen City Heart Study is a longitudinal 
cohort study designed to identify and characterize risk 
factors for CVD in the general population. The study 
population is based in and around the city of Copen-
hagen, Denmark. The population has been previously 
described in extensive detail [14–17]. This echocar-
diographic sub study included all participants who had 
an echocardiographic exam including tissue Doppler 
imaging performed in the 4th round of examination, 
conducted from 2001 to 2003. Whether any specific 
participant underwent an echocardiographic exam was 
independent of both health status and risk factors. Fig-
ure  1 displays the flow diagram for the study sample 
selection process. Initially, 2221 participants underwent 
echocardiography including tissue Doppler echocardiog-
raphy (Fig. 1). A total of 241 participants were excluded 
due to prevalent diabetes (Fig. 1). Then 270 participants 
had to be excluded due to missing LV chamber dimen-
sions (Fig. 1). This left 1710 participants for inclusion into 
the study (Fig. 1). In the final cohort, no participants had 
significant valvular disease.
Fig. 1 Flow diagram of the study sample selection process. TDI tissue Doppler imaging, LV left ventricle
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Ethics
Written consent was collected from all participants. The 
study complies with the second declaration of Helsinki. 
The design of the study was approved by a regional scien-
tific ethics committee.
Health examination
All participants underwent a general health examination 
consisting of a questionnaire and a physical examination. 
Blood pressure readings were obtained by sphygmoma-
nometer. Plasma cholesterol and plasma glucose levels 
were collected using non-fasting venous blood samples 
[18]. Plasma-pro-BNP (pro B-type natriuretic pep-
tide) was measured by a processing-independent assay 
and abnormal values defined as pro-BNP > 150  pmol/L. 
Prevalent DM was defined as either a plasma glucose 
level ≥ 11.1  mmol/L or HbA1c ≥ 7.0% or the use of glu-
cose-lowering medication [19]. Prevalent ischemic heart 
disease (IHD) was defined as either a history of admis-
sion for acute coronary artery occlusion, percutaneous 
coronary intervention, coronary artery bypass grafting 
or major electrocardiogram alterations per Minnesota 
codes 1.1 to 3.
Echocardiographic examination
Echocardiographic examinations were carried out by 
3 experienced sonographers using Vivid 5 Ultrasound 
machines (GE Healthcare, Horten, Norway) with a 
2.5  MHz transducer. All participants were subject to 
both conventional 2D-imaging and color tissue Dop-
pler imaging (TDI). Echocardiograms were stored on 
magneto-optical disks and on an external FireWire hard-
drive (Lacie, France). All echocardiograms underwent 
offline analysis by experienced investigators blinded to all 
clinical data and information about outcomes using com-
mercially available software (EchoPac, GE Healthcare, 
Horten, Norway).
Conventional echocardiography
Wall motion score indexing (WMSI) was determined 
using the 16-segment model as directed by the Ameri-
can Society of Echocardiography [20] with subsequent 
estimation of the left ventricular ejection fraction (LVEF) 
from the WMSI-score. An M-mode still frame perpen-
dicular to the long axis of the LV at the level of the mitral 
valve leaflets was used to determine LV diastolic dimen-
sions and LV wall dimensions. Left ventricular mass 
index (LVMI) was derived by indexation of LV mass with 
body surface area (BSA). Relative wall thickness (RWT) 
was calculated by indexation of the posterior wall thick-
ness (PWT) with the left ventricular internal diameter 
at end diastole (LVIDd) (RWT = 2 * PWT/LVIDd) [20]. 
LV hypertrophy categories were defined from RWT and 
LVMI as directed in contemporary guidelines [20]. LV 
concentric geometry was defined as either LV concen-
tric remodelling (RWT > 0.42 and LVMI ≤ 115 for men 
or RWT > 0.42 and LVMI ≤ 95 for women) or LV con-
centric hypertrophy (RWT > 0.42 and LVMI ≥ 115 for 
men or RWT > 0.42 and LVMI ≥ 95for women [20]. Aver-
age wall thickness was defined as the sum of interven-
tricular septum diameter (IVSD) and PWT divided by 
2 ((IVSD + PWT)/2). Mitral valve inflow patterns were 
determined using pulsed wave Doppler in the apical posi-
tion between the mitral valve leaflet tips. From here, peak 
early (E) and late (A) inflow velocity was measured and 
E/A ratio was calculated. Furthermore, the deceleration 
time of the E wave (DT) was measured.
Color tissue Doppler imaging
Color TDI velocity tracings were used to determine the 
peak longitudinal systolic velocity (s′), the early peak lon-
gitudinal diastolic velocity (e′) and the late longitudinal 
peak diastolic velocity (a′). In the 4-chamber view, the 
TDI range gate was placed in the septal and lateral posi-
tion of the mitral annulus with subsequent determination 
of peak velocities from the TDI velocity tracings. Thus, 
s′, e′ and a′ were calculated as the averages of the septal 
and lateral values. Aortic valve timings were determined 
using a 2–4 cm straight M-mode line through the septal 
half of the mitral leaflet in the color TDI 4-chamber view 
[15].
Follow‑up and outcome
Participants were followed from echocardiographic 
examination in 2001 to 2003 until time to event or, in the 
case of no event, until October 2014. The end-point of 
this study was incident DM. Follow-up data was collected 
through the Danish National Board of Health’s National 
Patient Registry using International Classification of 
Diseases, 10th revision codes (ICD). DM was defined as 
ICD-10 codes DE10-DE14.
Statistics
All statistical analysis was done using STATA 13 for Mac 
OS. A p-value < 0.05 was considered statistically signifi-
cant. In Table  1, continuous variables exhibiting Gauss-
ian distribution were compared using the two-tailed 
students t-test. Continuous variables not displaying 
Gaussian distribution were compared using the Mann–
Whitney U-test. Proportions were compared using the 
Chi squared test. In Table 2, univariable and multivaria-
ble Cox regression was used to assess prognostic strength 
of examined parameters. The extent of the multivariable 
analysis was limited by the relatively small number of 
events [21]. In Fig.  2, survival curves were constructed 
using the Kaplan–Meier method. In Fig. 3, Poisson cubic 
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Table 1 Baseline characteristics of participants stratified according to DM at follow-up
BP blood pressure, MAP mean arterial pressure, BMI body mass index, BPM beats per minute, AMI acute myocardial infarction, eGFR estimated glomerular filtration 
rate, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction, GLS global longitudinal strain, LVIDd left ventricular inner diameter at end diastole, LVMI left 
ventricular mass index, PWT posterior wall thickness, AWT average wall thickness, RWT relative wall thickness, IVSD interventricular septum diameter, LAVI left atrial 
volume index, DT deceleration time
Demographics All participants No DM DM p‑value
N 1710 1655 (96.8%) 55 (3.2%)
Age (years) 56.8 (16.3) 56.4 (16.4) 65.5 (10.9) < 0.001
Male 676 (39.5%) 648 (39.2%) 28 (50.9%) 0.08
Clinical characteristics
 Systolic BP (mmHg) 133.9 (22.4) 133.4 (22.4) 148.2 (18.6) < 0.001
 Diastolic BP (mmHg) 77.8 (12.0) 77.6 (12.1) 82.6 (10.3) 0.002
 Hypertension 665 (39.0%) 625 (37.9%) 40 (72.7%) < 0.001
 MAP (mmHg) 96.5 (13.9) 96.2 (13.9) 104.5 (11.2) < 0.001
 BMI (kg/m2) 25.1 (3.7) 25.0 (3.7) 28.6 (4.4) < 0.001
 Heart rate (BPM) 67 (11) 67 (11) 71 (11) 0.008
 Smoking 525 (30.7%) 504 (30.5%) 21 (38.2%) 0.22
 Ischemic heart disease 82 (4.8%) 74 (4.5%) 8 (14.5%) < 0.001
 Heart failure 16 (0.9%) 16 (1.0%) 0 (0%) 0.46
 Glucose (mmol/L) 5.5 (1.0) 5.5 (1.0) 6.2 (1.5) < 0.001
 HBA1c (%) 5.8 (0.5) 5.7 (0.5) 6.0 (0.5) < 0.001
 Triglycerides (mmol/L) 1.5 (0.8) 1.5 (0.8) 2.0 (1.2) < 0.001
 eGFR (mL/min) 76 (16) 76 (16) 76 (17) 0.94
 Pro‑BNP (pmol/L) 16, (8‑30) 16 (7‑30) 17 (11‑30) 0.47
 Total cholesterol (mmol/L) 5.5 (1.2) 5.5 (1.2) 5.7 (1.0) 0.30
 Blood pressure lowering medication 222 (13.0%) 202 (12.2%) 20 (36.4%) < 0.001
 Lipid lowering medication 224 (13.1%) 207 (12.5%) 17 (30.9%) < 0.001
Echocardiography
 LVEF (%) 59.7 (1.9) 59.7 (1.9) 59.9 (1.0) 0.61
 LVIDd/height (cm/m) 2.8 (0.3) 2.8 (0.3) 2.8 (0.3) 0.52
 LVMI (g/m2) 85.7 (22.1) 85.4 (21.9) 93.0 (24.4) 0.013
 PWT (cm) 0.9 (0.2) 0.9 (0.2) 1.0 (0.2) < 0.001
 AWT (cm) 0.9 (0.2) 0.9 (0.2) 1.0 (0.2) < 0.001
 RWT (cm) 0.38 (0.08) 0.37 (0.08) 0.42 (0.11) < 0.001
 IVSD (cm) 1.0 (0.2) 1.0 (0.2) 1.1 (0.2) < 0.001
 LV concentric geometry 361 (21.1%) 338 (20.4%) 23 (41.8%) < 0.001
LV hypertrophy categories < 0.001
 Normal geometry 1178 (69.1%) 1153 (69.9%) 25 (45.5%)
 Concentric remodeling 270 (15.8%) 253 (15.3%) 17 (30.9%)
 Eccentric hypertrohpy 166 (9.7%) 159 (9.6%) 7 (12.7%)
 Concentric hypertrohpy 91 (5.3%) 85 (5.2%) 6 (10.9%)
 LAVI (mL/m2) 19.4 (6.7) 19.4 (6.9) 20.2 (7.0) 0.44
 E (m/s) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.18
 A (m/s) 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) < 0.001
 E/A 1.2 (0.5) 1.2 (0.5) 0.9 (0.3) < 0.001
 E/e′ 10.9 (4.7) 10.8 (4.6) 13.2 (4.9) < 0.001
 DT (ms) 165 (39) 165 (39) 177 (42) 0.026
 s′ (cm/s) 5.9 (1.3) 6.0 (1.3) 5.7 (1.2) 0.16
 e′ (cm/s) 7.5 (2.7) 7.6 (2.7) 5.9 (2.2) < 0.001
 a′ (cm/s) 6.4 (1.9) 6.3 (1.9) 7.1 (1.9) 0.008
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Table 2 Baseline characteristics of participants stratified according to LV concentric geometry
BP blood pressure, MAP mean arterial pressure, BMI body mass index, BPM beats per minute, AMI acute myocardial infarction, eGFR estimated glomerular filtration 
rate, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction, GLS global longitudinal strain, LVIDd left ventricular inner diameter at end diastole, LVMI left 
ventricular mass index, PWT posterior wall thickness, AWT average wall thickness, RWT relative wall thickness, IVSD interventricular septum diameter, LAVI left atrial 
volume index, DT deceleration time
Demographics No LV concentric geometry LV concentric geometry p‑value
N 1349 (78.9%) 361 (21.1%)
Age (years) 54.6 (16.2) 64.8 (14.0) < 0.001
Male 541 (40.1%) 135 (37.4%)
Clinical characteristics
 Systolic BP (mmHg) 131.4 (22.1) 143.2 (21.2) < 0.001
 Diastolic BP (mmHg) 77.0 (11.5) 80.7 (13.6) < 0.001
 Hypertension 450 (33.4%) 215 (59.6%) < 0.001
 MAP (mmHg) 95.1 (13.6) 101.6 (14.0) < 0.001
 BMI (kg/m2) 25.0 (3.7) 25.7 (3.9) 0.001
 Heart rate (BPM) 66 (11) 68 (12) 0.006
 Smoking 406 (30.1%) 119 (33.0%) 0.29
 Ischemic heart disease 59 (4.4%) 23 (6.4%) 0.11
 Heart failure 11 (0.8%) 5 (1.4%) 0.32
 Glucose (mmol/L) 5.4 (1.0) 5.7 (1.1) < 0.001
 HBA1c (%) 5.7 (0.5) 5.8 (0.5) 0.23
 Triglycerides (mmol/L) 1.5 (0.8) 1.6 (0.9) 0.021
 eGFR (mL/min) 77 (16) 74 (16) < 0.001
 Pro‑BNP (pmol/L) 15 (7–28) 20 (9–37) < 0.001
 Total cholesterol (mmol/L) 5.5 (1.1) 5.8 (1.3) < 0.001
 Blood pressure lowering medication 139 (10.3%) 83 (23.0%) < 0.001
 Lipid lowering medication 151 (11.2%) 73 (20.2%) < 0.001
Echocardiography
 LVEF (%) 59.7 (2.0) 59.8 (1.0) 0.24
 LVIDd/height (cm/m) 2.9 (0.3) 2.6 (0.3) < 0.001
 LVMI (g/m2) 83.7 (20.8) 93.0 (25.0) < 0.001
 PWT (cm) 0.8 (0.1) 1.1 (0.1) < 0.001
 AWT (cm) 0.9 (0.1) 1.1 (0.2) < 0.001
 RWT (cm) 0.34 (0.05) 0.49 (0.07) < 0.001
 IVSD (cm) 0.9 (0.2) 1.1 (0.2) < 0.001
LV hypertrophy categories N/A
 Normal geometry 1178 (87.6%) 0
 Concentric remodeling 0 270 (74.8%)
 Eccentric hypertrohpy 166 (12.4%) 0
 Concentric hypertrohpy 0 91 (25.2%)
 LAVI (mL/m2) 19.4 (6.7) 19.6 (7.6) 0.56
 E (m/s) 0.7 (0.2) 0.7 (0.2) < 0.001
 A (m/s) 0.7 (0.2) 0.7 (0.2) < 0.001
 E/A 1.2 (0.5) 1.0 (0.4) < 0.001
 E/e′ 10.4 (4.2) 12.8 (5.9) < 0.001
 DT (ms) 163 (36) 174 (49) < 0.001
 s′ (cm/s) 6.0 (1.3) 5.7 (1.3) < 0.001
 e′ (cm/s) 7.8 (2.7) 6.2 (2.3) < 0.001
 a′ (cm/s) 6.2 (1.9) 6.9 (1.8) < 0.001
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spline regression was used to estimate incidence rates 
of DM using RWT as a continuous measure of LV con-
centricity. In Fig. 4, Cox cubic spline regression was used 
to estimate the hazard ratio associated with increasing 
degree of LV concentricity evaluated as RWT. In Figs. 3 
and 4 the number of knots were selected by calculating 
Fig. 2 Incident diabetes mellitus stratified by left ventricular (LV) concentric geometry at baseline
Fig. 3 Long‑term risk of incident diabetes mellitus as a function of the degree of left ventricular (LV) concentricity quantified as relative wall 
thickness (RWT)
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the Akaike Information Criterion (AIC) for each model 
with subsequent selection of the model displaying 
the lowest value. In Fig.  5 we studied the relationship 
between the degree of LV concentricity evaluated as 
RWT and diastolic function as quantified by E/e′ and e′ 
using restricted cubic spline regression. For the number 
of knots we chose the best fitting model as determined 
by the lowest AIC. We used Net Reclassification Analysis 
[22] and Integrated Discrimination Improvement Analy-
sis [22] to evaluate the incremental prognostic value of 
LV concentric geometry and RWT in predicting DM over 
a model of established risk factors for DM. This model 
was limited by the number of events (n = 55) in the final 
multivariable model and hence the following risk fac-
tors were chosen: age, sex, systolic blood pressure, total 
cholesterol, triglycerides, HbA1c levels, and BMI. Finally, 
we assessed whether treating death as a competing event 
in competing risk Cox regressions changed our results 
(Additional file 1: Table S1).     
Results
Population, outcome and follow‑up
Median follow-up time was 12.6  years (IQR: 12.0–
12.8  years). Follow-up was a 100%. End-point was inci-
dent DM. A total of 55 participants (3.3%) developed DM 
during follow-up.
Baseline characteristics of the population stratified per DM 
at follow‑up
Participants who developed DM were significantly older 
and displayed higher values of systolic blood pressure 
(BP), diastolic BP and mean arterial pressure (Table  1). 
Also, they displayed higher values of body mass index and 
heart rate, and the prevalence of IHD was higher among 
participants who developed DM (Table 1). Furthermore, 
they displayed significantly higher values of blood glu-
cose, HbA1c levels and blood triglycerides (Table 1).
Participants who developed DM displayed higher val-
ues of LVMI, PWT, average wall thickness, RWT, IVSD, 
A, E/e′, DT and a′ (Table 1). Individuals who developed 
DM displayed significantly lower values of E/A, s′ and e′ 
(Table 1). The prevalence of LV concentric remodelling, 
LV concentric hypertrophy and LV concentric geometry 
was significantly higher in participants who developed 
DM during follow-up (Table 1). Notably, at baseline, the 
prevalence of LV concentric geometry was twice as high 
(20% vs 42%, p < 0.001) in individuals who developed DM 
during follow-up.
Baseline characteristics stratified per LV concentric 
geometry
Participants with concentric LV geometry were charac-
terized by higher blood pressure, higher body mass index 
Fig. 4 Long‑term relative risk of incident diabetes mellitus as a function of the degree of left ventricular (LV) concentricity quantified as relative wall 
thickness (RWT). The y‑axis is logarithmically scaled
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and higher heart rate (Table  2). Blood levels of glucose, 
triglycerides, total cholesterol and pro-BNP were also 
significantly higher in participants with concentric LV 
geometry (Table  2). They also had significantly higher 
LVMI, PWT, average wall thickness, RWT, IVSD, A, E/e′, 
DT and a′ (Table  2). Finally, they displayed significantly 
lower values of LVIDd/height, E, E/A, s′ and e′ (Table 2).
Fig. 5 The association between LV concentricity quantified as relative wall thickness and diastolic function as determined by e′ and E/e′
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Prediction of incident DM in the general population
In univariable Cox regression, LV concentric geometry, 
LVMI, IVSD, PWT, average wall thickness, RWT, A, E/A 
E/e′, DT, e′ and a′ were significant predictors of incident 
DM (Table  3). In univariable Cox regression, individu-
als with LV concentric geometry exhibited an approx. 3 
times greater risk of developing DM compared to par-
ticipants without LV concentric geometry (Fig.  2). Both 
LV concentric remodelling and LV concentric hypertro-
phy were associated with an increased risk of developing 
DM, and no statistically significant difference in risk was 
present between the two groups (LV concentric remodel-
ling: HR 3.22, 95% CI 1.74–5.98, p < 0.001) (LV concentric 
hypertrophy: HR 3.61, 95% CI 1.48-8.80, p = 0.005) (p for 
difference: p = 0.81). In univariable Cox regression inter-
action analysis, the association between LV concentric 
geometry or RWT and DM was not significantly modi-
fied by sex (LV concentric geometry, p for interaction: 
p = 0.19) (RWT, p for interaction: p = 0.88). Additionally, 
the risk of developing DM during follow-up increased 
exponentially with increasing degree of LV concentricity 
evaluated as RWT (Figs. 3 and 4).
In a multivariable model (Model 1, Table  3) adjusting 
for age, sex, hypertension, smoking status, total cho-
lesterol levels, blood triglycerides, BMI, blood glucose, 
HbA1c levels, pro-BNP, prevalent IHD and prevalent 
HF, only A, RWT and LV concentric geometry remained 
independent predictors of DM (Table 3). In a final mul-
tivariable model (Model 2, Table  3) adjusting for the 
same variables as Model 1 with further adjustment for A, 
only RWT and LV concentric geometry remained inde-
pendent predictors of DM (Table  3). Additional adjust-
ment of our final multivariable model for either blood 
pressure lowering or lipid lowering medication did not 
attenuate the prognostic value of RWT and LV concen-
tric geometry (Lipid lowering: Concentric geometry HR 
1.83, 95%CI 1.01–3.30, p = 0.046; RWT HR 1.35, 95%CI 
1.02–1.78, per 0.1 increase, p = 0.037) (blood pressure 
lowering: concentric geometry HR 1.98, 95%CI 1.10–
3.56, p = 0.022; RWT HR 1.43, 95%CI 1.07–1.90, per 0.1 
Table 3 Echocardiographic predictors of incident DM (n = 55) using Cox regression
Model 1 is adjusted for age, sex, hypertension, smoking status, total cholesterol levels, triglyceride levels, BMI, blood glucose, HbA1C levels, pro-BNP, prevalent 
ischemic heart disease and prevalent heart failure. Model 2 is adjusted for the same variables as Model 1 with the addition of A. In the multivariable models, only 
parameters reaching statistical significance are shown
LVIDD/height left ventricular internal diameter at end diastole indexed to height, LVMI left ventricular mass index, IVSD interventricular septum diameter, PWT 
posterior wall thickness, AWT average wall thickness, RWT relative wall thickness, LAVI left atrial volume index, DT deceleration time
Unadjusted Hazard ratio p‑value
LV concentric geometry HR 2.92, 95% CI 1.71–5.00 < 0.001
LVIDD/height (per 1 cm/m increase) HR 0.73, 95% CI 0.0.29–1.87 0.51
LVMI (per 5 g/m2 increase) HR 1.08, 95% CI 1.02–1.13 0.004
IVSD (per 1 mm increase) HR 1.31, 95% CI 1.18–1.46 < 0.001
PWT (per 1 mm increase) HR 1.35, 95% CI 1.20–1.52 < 0.001
AWT (per 1 mm increase) HR 1.49, 95% CI 1.30–1.71 < 0.001
RWT (per 0.1 increase) HR 1.71, 95% CI 1.38–2.12 < 0.001
LAVI (per 1 mL/m2 increase) HR 1.02, 95% CI 0.99–1.06 0.20
E (per 10 cm/s decrease) HR 1.13, 95% CI 0.95–1.34 0.17
A (per 10 cm/s increase) HR 1.50, 95% CI 1.33–1.70 < 0.001
E/A ratio (per 0.1 decrease) HR 1.27, 95% CI 1.15–1.40 < 0.001
E/e′ ratio (per 1 increase) HR 1.09, 95% CI 1.05–1.13 < 0.001
DT (per 10 ms increase) HR 1.08, 95% CI 1.02–1.14 0.009
s′ (per 1 cm/s increase) HR 0.81, 95% CI 0.64–1.02 0.07
e′ (per 1 cm/s increase) HR 0.76, 95% CI 0.67–0.85 < 0.001
a′ (per 1 cm/s increase) HR 1.22, 95% CI 1.05–1.40 0.008
Model 1 Hazard ratio p‑value
A (per 10 cm/s increase) HR 1.22, 95% CI 1.02–1.46 0.028
LV Concentric Geometry HR 1.92, 95% CI 1.09–3.38 0.023
RWT (per 0.1 increase) HR 1.43, 95% CI 1.09–1.87 0.009
Model 2 Hazard ratio p‑value
LV Concentric Geometry HR 1.99, 95% CI 1.11–3.57 0.021
RWT (per 0.1 increase) HR 1.41, 95% CI 1.06–1.86 0.017
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increase, p = 0.014). The results were similar in compet-
ing risk regression treating death as a competing event 
(Additional file 1: Table S1).
Association of RWT with diastolic function
In restricted cubic spline regression LV concentricity as 
evaluated by RWT was significantly associated with dias-
tolic function (Fig. 5). Diastolic function evaluated as e′ 
and E/e′ declined with increasing degree of LV concen-
tricity (Fig. 5).
Incremental prognostic value in addition to established 
risk factors for development of DM
We assessed the incremental prognostic value of myocar-
dial indices derived from echocardiography when added 
to already established risk factors for DM (age, sex, total 
cholesterol, triglycerides, haemoglobin A1C levels, sys-
tolic blood pressure, and BMI). In reclassification analy-
sis, only RWT and LV concentric geometry provided 
incremental prognostic value when added to established 
risk factors (LV concentric geometry: Continuous NRI 
0.429, 95% CI 0.023–0.680; IDI 0.010, 95%CI 0.000–
0.033) (RWT: continuous NRI 0.431, 95% CI 0.040–0.760; 
IDI 0.008, 95%CI 0.000–0.037).
Discussion
In this general population study, we demonstrate that 
measures of LV structure derived from an echocardio-
graphic examination independently predict the develop-
ment of DM 10 years following examination. Specifically, 
we demonstrate that a LV concentric geometric pattern 
is an independent predictor of DM in the general popu-
lation, even after adjustment for established risk factors 
for DM. Furthermore, we show that the risk of incident 
DM rises continuously with increasing degree of LV con-
centricity as evaluated by RWT. Finally, we show that this 
prognostic information is incremental to established pre-
dictors of DM, indicative of a strong association between 
LV concentric geometry and DM.
Echocardiography, DM and diabetic cardiomyopathy
The notion of a true and distinct diabetic cardiomyopathy 
has been around for a long time, dating all the way back 
to the 1950s when Lundbæk, an internist in Denmark, 
observed frequent myocardial dysfunction in elderly 
patients with DM [23]. He suggested that DM patients 
may have heart disease in the absence of coronary block-
age [23]. He became the first to suggest the existence of 
a specific diabetic form of cardiomyopathy. Now, two 
distinct phenotypes of diabetic cardiomyopathy have 
been suggested: an eccentric, dilated form with reduced 
systolic function (HFrEF phenotype), and a restricted, 
concentric form characterized by diastolic dysfunction 
(HFpEF phenotype) [13]. The HFpEF phenotype is the 
one most often encountered by clinicians [13]. Several 
cross-sectional studies have demonstrated impaired dias-
tolic function and increased LV mass in DM individuals 
[4, 5, 7, 24]. In our study, diastolic parameters (A, DT, 
E/A, E/e′, e′, a′) were impaired and LVMI was increased 
in participants who developed DM during follow-up, 
supporting the findings of previous studies. However, 
only peak A-wave remained significant after adjustment 
for clinical characteristics, suggesting that the prognos-
tic value of the other diastolic parameters was secondary 
to associations with clinical characteristics. In early dias-
tolic dysfunction and with increasing age along with sub-
tle wall hypertrophy, the A wave increases in magnitude 
due to increased atrial contribution to LV filling to com-
pensate for the decreased inflow during early diastole (E 
wave), often referred to as “atrial kick” [25]. However, 
peak A-wave did not remain significant in a final model 
adjusting for clinical characteristics and LV concentric 
geometry. In this model, only LV concentric geometry 
and RWT were independent predictors of outcome, sug-
gesting that the significance of A was secondary to clini-
cal characteristics and the degree of LV concentricity. It 
is widely recognized that cardiac concentric remodel-
ling can contribute to diastolic dysfunction, and thus our 
results support the hypothesis that diastolic parameters 
are associated with DM secondary to LV concentricity. 
A recent study by our group, examining cardiac function 
in a population of DM individuals, found that individu-
als with DM were mainly characterized by increased LV 
concentricity evaluated as RWT due to increased LV 
wall thickness and smaller LV cavities [7]. In the same 
study, we found that the severity of LV concentricity 
evaluated by RWT correlated significantly to the dura-
tion of DM [7]. Similar relationships between DM and 
LV concentricity have been found by other authors: In a 
recent cross-sectional study of type 2 DM patients, De 
Jong et al. [26] reported that LV concentricity and RWT 
were significantly increased in both obese and non-obese 
type 2 DM patients as compared to metabolically healthy 
obese patients, even in the absence of hypertension. Rob-
erts et  al. [27] compared the exercise capacity of type 2 
DM patients to that of healthy age and sex-matched 
controls and found that increased sedentary behaviour 
and reduced LVIDd were significantly associated with 
reduced exercise capacity in patients with type 2 DM (in 
addition, type 2 DM patients also displayed increased 
RWT as compared to healthy controls). These findings 
concur with our results, since LV concentric geometry 
and RWT were the only echocardiographic predictors of 
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incident DM in the present study, and since the risk of 
DM increased continuously with increasing degree of LV 
concentricity as evaluated by RWT, suggesting that LV 
concentricity is indeed correlated to abnormal glucose 
metabolism.
The finding that the prognostic value of diastolic 
parameters is secondary to indices of LV concentric-
ity is supported by the suspected pathophysiological 
mechanisms underlying diabetic cardiomyopathy. It is 
thought, in the HFpEF phenotype, that hyperglycaemia, 
lipotoxicity and insulin resistance cause cardiomyocyte 
hypertrophy and increased resting tension, along with 
collagen deposition between cells [13]. This leads to LV 
wall thickening with a concomitant increase in stiffness 
and decrease in diastolic function. These pathophysi-
ological considerations are reflected in our results, since 
participants with concentric LV geometry had signifi-
cantly higher levels of blood glucose, blood triglycerides 
and cholesterol levels. They also had significantly higher 
body mass index and blood pressure and lower estimated 
glomerular filtration rates. These are all risk factors for 
CVD [28–31], and they contribute significantly to the 
increased risk of CVD seen in DM [32]. Thus, the degree 
of LV concentricity appears to scale with the degree of 
dyslipidaemia, hyperglycaemia, hypertension, and body 
mass index even before development of DM, supporting 
its prognostic value in predicting DM.
Target organ damage and prediction of DM
Conventionally, it has been thought that a clear tempo-
ral relationship existed between cardiovascular risk fac-
tors and the development of end organ damage such as 
LV diastolic dysfunction, LV hypertrophy and LV systolic 
impairment. However, it has recently been shown that 
LV hypertrophy and arterial stiffness, markers of end 
organ damage, are predictors of incident hypertension in 
both normotensive and prehypertensive individuals [33, 
34]. This raises questions about the temporal relation-
ship between cardiovascular risk factors and end organ 
damage, indicating that end organ damage may contrib-
ute with novel prognostic value. Besides our study, one 
study has previously investigated the prognostic role of 
echocardiography with respect to development of DM 
in the general population. In this study, Park and Col-
leagues investigated the prognostic value of echocardi-
ography in predicting incident type 2 DM in a cohort of 
1817 non-diabetic individuals from Korea [9]. The age 
of their population was lower (mean 54  years vs mean 
57.9  years) and the follow-up was shorter (6  years vs 
median 12.6  years) when compared to our study. Also, 
the prevalence of hypertension in their sample was much 
lower (22.1% vs 38.7%) than in our sample indicative of a 
younger and healthier population. During follow-up 273 
individuals (15%) developed type 2 DM, which is higher 
than what we found in our study. This may be explained 
by the lower age of their study sample. Due to the higher 
age of participants in our study many had already devel-
oped DM at baseline and were therefore excluded. Park 
and Colleagues found that markers of diastolic dysfunc-
tion (e′ and E/e′) predicted incident DM. After adjust-
ment for clinical risk factors, only e’ and the presence of 
diastolic dysfunction (yes/no) were independent predic-
tors of DM. No results regarding the prognostic value of 
LV concentric geometry or RWT in predicting DM in the 
final multivariable model are shown, however, RWT was 
significantly higher in individuals who developed type 2 
DM during follow-up (0.39 SD 0.07 vs 0.36 SD 0.06). This 
suggests that LV concentric geometry may have been an 
independent predictor of DM in their study as well, how-
ever no results regarding LV concentric geometry was 
reported. Nevertheless, it is possible that the prognostic 
value of echocardiography differs between ethnicities 
with regards to prediction of DM. Hence more research 
is needed to explain the differences between our two 
studies. However, altered LV concentricity seems to cor-
respond more closely to the pathophysiological mecha-
nisms suspected to underlie the cardiac alterations seen 
in the HFpEF phenotype of diabetic cardiomyopathy, 
and our results suggest that the predictive value of many 
diastolic parameters in predicting DM is secondary to LV 
concentric geometry. To our knowledge, ours is the sec-
ond study to evaluate the prognostic value of echocardi-
ography in predicting development of DM in the general 
population, and therefore, our results should be viewed 
as exploratory and hypothesis generating. More research, 
by independent groups in similar populations, is needed 
before any significant conclusions can be drawn. In sum-
mary, we show that end organ damage can contribute 
with prognostic value in predicting DM in the general 
population, and that this organ damage precedes the 
development of DM.
Limitations and future considerations
Several limitations to this study must be acknowledged. 
Firstly, mean age at baseline of participants included into 
this study was 56.6  years (SD: 16.3  years), and thus the 
prevalence of DM before exclusion of diabetic individu-
als was 10.9% (241 individuals). These were all excluded 
from the study. Therefore, due to the high age of this gen-
eral population sample, a large proportion had already 
developed DM at baseline and were therefore excluded. 
Furthermore, we assessed the development of DM by 
ICD-10 codes, and therefore we do not know how rigor-
ously or by what methods participants have been moni-
tored for the development of DM. Due to unknown 
differences in the rigour of monitoring of participants, the 
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time from echocardiographic examination to DM diag-
nosis may have been overestimated, since participants 
may not have sought out medical consultation at the 
onset of symptoms from DM. This could potentially alter 
the temporal relationship between RWT values and DM 
development observed in this study. Furthermore, in the 
Copenhagen City Heart study, prevalent DM was defined 
using the old HbA1c cut-off value (HbA1c ≥ 7.0%). Today 
a cut-off value of HBA1c ≥ 6.5% is used [35]. Therefore, 
our definition of prevalent DM may have underestimated 
the true prevalence. Also, the general population in Den-
mark is mainly of Caucasian ethnicity, and therefore we 
cannot extrapolate our results to other races—stressing 
this is particularly important when considering ethnic-
ity in itself is a significant risk factor for DM, and that 
ethnicity modifies the contributions of many other risk 
factors for cardiovascular disease in diabetic individuals 
[11, 12]. We did not have information on the prevalence 
of rare cardiomyopathies such as hypertrophic car-
diomyopathy, which may affect LV geometry. However, 
undiagnosed cases of rare cardiomyopathies are unlikely 
to have affected our results given their very low preva-
lence in the general population. Also, since rare cardio-
myopathies do not cause DM, potential inclusion of such 
patients would only serve to weaken our results. Yet, we 
still found significant associations between LV concen-
tric geometry and DM. A final limitation is related to the 
method of outcome assessment in the present study. In 
this study, DM outcomes were assessed through the Dan-
ish National Board of Health’s National Patient Registry 
using ICD 10 codes. However, this means that receiving a 
diagnosis of DM necessitates some type of hospital con-
tact. This hospital contact can either be directly related to 
DM, or it can be unrelated to the presence of DM and the 
presence of DM may then be discovered through patient 
history or examination/assessment. Given the long fol-
low-up of our study (median 12.6 years) and the high age 
of participants at baseline (mean 57  years) it is reason-
able to assume that most patients will have at least one 
hospital contact not related to a potential DM diagnosis 
facilitating the discovery of DM if present. Yet, this does 
constitute a limitation of the present study and could 
have affected our results. In addition, it is also possible 
that the DM outcomes detected may represent sicker DM 
patients possibly requiring hospitalisation at DM debut 
since outcome assessment is related to hospital contact. 
Thus, although our study provides important hypothesis 
generating results, ideally, our findings should be evalu-
ated in multiple ethnicities, in a younger study popula-
tion and using a study design including closer, dedicated 
outcome assessment.
Conclusion
Altered LV geometry may precede the development of 
DM. LV concentric geometry determined by echocardi-
ography and the severity of LV concentricity evaluated as 
RWT are independent predictors of incident DM in the 
general population.
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